Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd (LINCOLN) last traded at ₹618, a market capitalisation of ₹1,238 crore, on a P/E of 12.8. Over the past 52 weeks the stock has ranged between ₹440 and ₹770. Lincoln Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹177 crore and net profit of ₹36 crore. Figures are as of 25 Aug 2026 and are not real time.
Lincoln Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Lincoln Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹177 cr, up 14.9% from ₹154 cr a year earlier. Net profit was ₹36 cr, up 28.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating profit | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% |
| Other income | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% |
| Net profit | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS (₹) | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Lincoln Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 424 | 472 | 510 | 581 | 623 | 671 | 694 |
| Operating profit | 87 | 96 | 90 | 100 | 102 | 98 | 101 |
| OPM % | 21% | 20% | 18% | 17% | 16% | 15% | 15% |
| Net profit | 62 | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS (₹) | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 | 43.88 | 48.16 |
TTM is the trailing twelve months to the most recent quarter.
Lincoln Pharmaceuticals Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- 10%
- 10 Years
- 14%
- 5 Years
- 7%
- 3 Years
- 7%
- TTM
- 12%
- 10 Years
- 11%
- 5 Years
- 13%
- 3 Years
- 8%
- 1 Year
- 12%
- 10 Years
- 16%
- 5 Years
- 15%
- 3 Years
- 14%
- Last Year
- 12%
Lincoln Pharmaceuticals Ltd shareholding pattern
Promoters held 49.78% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.60% and DIIs 0.27%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| FIIs | 5.19% | 5.16% | 5.00% | 5.13% | 4.73% | 4.70% | 5.20% | 4.60% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 1.08% | 0.27% |
| Public | 45.04% | 45.07% | 45.23% | 45.08% | 45.49% | 45.51% | 43.94% | 45.36% |
| No. of shareholders | 31,330 | 31,848 | 31,867 | 31,784 | 32,370 | 31,026 | 28,303 | 29,396 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Lincoln Pharmaceuticals Ltd corporate filings
- We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June, 2026.Company Updatelow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has published the mandatory newspaper advertisement…
Read the full analysis - Un-Audited Financial Results of the Company For the Quarter Ended June 30, 2026.Board Meetinghigh impact
Cruxal's analysis: Lincoln Pharmaceuticals Ltd reported strong Q1 FY27 performance with consolidated net…
Read the full analysis - Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Lincoln Pharmaceuticals ....Board Meetinglow impact
Cruxal's analysis: Lincoln Pharmaceuticals Limited has formally notified the stock exchanges of a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Lincoln Pharmaceuticals Ltd
Cruxal reads every Lincoln Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.